BIOMAT Database Logo BIOMAT Database Logo

Clozapine in severe conduct disorder. 2013

Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Department of Psychiatry, State University of Campinas (UNICAMP), São Paulo State, Brazil . eduardo@psiquiatriaforense.com.br

METHODS An open, naturalistic observational study design was used, in which a sample of seven boys between 10 and 14 years of age was assessed over 26 weeks. RESULTS The subjects were all diagnosed with conduct disorder (CD) and exhibited high levels of aggression that were refractory to psychosocial approaches (parent counseling, school counseling, and psychotherapy) and to more than three pharmacological treatments. Levels of aggression, side effects, and hematological parameters were evaluated weekly. Clinical response was evaluated using the standardized instruments Clinical Global Impressions (CGI) and Child Behavior Check List (CBCL) 6-18 before starting medication and after 26 weeks. CONCLUSIONS We observed good tolerability of clozapine in doses from 100 to 600 mg/day with no significant side effects or hematological changes. The CGI and CBCL 6-18 scales indicated that clozapine led to a marked control of symptoms.

UI MeSH Term Description Entries
D008297 Male Males
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002652 Child Behavior Any observable response or action of a child from 24 months through 12 years of age. For neonates or children younger than 24 months, INFANT BEHAVIOR is available. Behavior, Child
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000294 Adolescent Behavior Any observable response or action of an adolescent. Behavior, Adolescent,Adolescent Behaviors,Behaviors, Adolescent
D000374 Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism. Aggressions
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Prefrontal lobotomy for severe conduct disorder.
August 1947, Archives of neurology and psychiatry,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Severe conduct disorder--some key issues.
August 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Severe conduct disorder and hyperkinetic conduct disorder in childhood is associated with criminality in later life.
November 2011, Evidence-based mental health,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Olanzapine treatment in adolescents with severe conduct disorder.
January 2006, European psychiatry : the journal of the Association of European Psychiatrists,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Treatment of severe borderline personality disorder with clozapine.
July 2010, Indian journal of psychiatry,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Comparison between conduct disorder and hyperkinetic conduct disorder.
January 2000, Indian journal of psychiatry,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Conduct disorder.
January 1991, Journal of child psychology and psychiatry, and allied disciplines,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Conduct disorder.
June 2019, Nature reviews. Disease primers,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Conduct disorder.
June 2019, Nature reviews. Disease primers,
Eduardo H Teixeira, and Eloisa V Celeri, and Antonio C A Jacintho, and Paulo Dalgalarrondo
Conduct disorder.
November 2007, Pediatrics in review,
Copied contents to your clipboard!